impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer
Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailable estrogens by inhibiting aromatase, which would be expected to induce alterations in body composition, more extensive than induced by menopause. The o...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2011-01, Vol.125 (2), p.441-446 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 446 |
|---|---|
| container_issue | 2 |
| container_start_page | 441 |
| container_title | Breast cancer research and treatment |
| container_volume | 125 |
| creator | van Londen, G. J Perera, S Vujevich, K Rastogi, P Lembersky, B Brufsky, A Vogel, V Greenspan, S. L |
| description | Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailable estrogens by inhibiting aromatase, which would be expected to induce alterations in body composition, more extensive than induced by menopause. The objectives are to examine the impact of AIs on (1) DXA-scan derived body composition and (2) gonadal hormone levels. This is a sub-analysis of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate (35 mg once weekly) versus placebo, and stratified for their usage of AI versus no AI. Outcomes included DXA-scan derived body composition and gonadal hormone levels. As a group, total body mass increased in women over 24 months. Women on AIs gained a significant amount of lean body mass compared to baseline as well as to no-AI users (P < 0.05). Women not on an AI gained total body fat compared to baseline and AI users (P < 0.05). Free testosterone significantly increased and sex hormone binding globulin (SHBG) significantly decreased in women on AIs compared to no AIs at 24 months (P < 0.01) while total estradiol and testosterone levels remained stable. Independent of AI usage, chemotherapy-induced postmenopausal breast cancer patients demonstrated an increase of total body mass. AI users demonstrated maintenance of total body fat, an increase in lean body mass and free testosterone levels, and a decrease in SHBG levels compared to no-AI users. The mechanisms and implications of these changes need to be studied further. |
| doi_str_mv | 10.1007/s10549-010-1223-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3103776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A356352667</galeid><sourcerecordid>A356352667</sourcerecordid><originalsourceid>FETCH-LOGICAL-c620t-8229411b0a6325e8039d0874e702f7ab58df2665af4382cb690ca6988566c2203</originalsourceid><addsrcrecordid>eNp9kl9vFCEUxSdGY7fVD-CLEo2-Tb3ADDAvTZqm_kma-KB9JncYZoc6AyvM1vTby2bWtpsYQwIBfucAh1sUryicUgD5MVGoq6YECiVljJfsSbGiteSlZFQ-LVZAhSyFAnFUHKd0AwCNhOZ5ccQoVIJxtip-ummDZiahJ-gJxjDhjMkS5wfXujlEEjxpQ3dHTJg2IbnZ5QX0HVkHjx2OZAhxCt6S0d7aMWUh-R0mm3s3D6SNFtNMDHpj44viWY9jsi_340lx_enyx8WX8urb568X51elEQzmUjHWVJS2gIKz2irgTQdKVlYC6yW2tep6JkSNfcUVM61owKBolKqFMIwBPynOFt_Ntp1sZ6yfI456E92E8U4HdPpwx7tBr8Ot5hS4lCIbvN0bxPBra9Osb8I2-nxnrRjlIEDwDL1boDWOVjvfh-xlJpeMPue14HW-o8zU6T-o3Do7OZNz611ePxB8eCQYLI7zkMK43eWeDkG6gCaGlKLt7x9IQe_KQy_loWE3z-WhWda8fpzMveJvPWTg_R7AZHDsY_44lx44LivJaZU5tnApb_m1jQ8J_e_0N4uox6BxHbPx9XcGOVDaMKpqyv8AIjvZaA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>821306063</pqid></control><display><type>article</type><title>impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>van Londen, G. J ; Perera, S ; Vujevich, K ; Rastogi, P ; Lembersky, B ; Brufsky, A ; Vogel, V ; Greenspan, S. L</creator><creatorcontrib>van Londen, G. J ; Perera, S ; Vujevich, K ; Rastogi, P ; Lembersky, B ; Brufsky, A ; Vogel, V ; Greenspan, S. L</creatorcontrib><description>Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailable estrogens by inhibiting aromatase, which would be expected to induce alterations in body composition, more extensive than induced by menopause. The objectives are to examine the impact of AIs on (1) DXA-scan derived body composition and (2) gonadal hormone levels. This is a sub-analysis of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate (35 mg once weekly) versus placebo, and stratified for their usage of AI versus no AI. Outcomes included DXA-scan derived body composition and gonadal hormone levels. As a group, total body mass increased in women over 24 months. Women on AIs gained a significant amount of lean body mass compared to baseline as well as to no-AI users (P < 0.05). Women not on an AI gained total body fat compared to baseline and AI users (P < 0.05). Free testosterone significantly increased and sex hormone binding globulin (SHBG) significantly decreased in women on AIs compared to no AIs at 24 months (P < 0.01) while total estradiol and testosterone levels remained stable. Independent of AI usage, chemotherapy-induced postmenopausal breast cancer patients demonstrated an increase of total body mass. AI users demonstrated maintenance of total body fat, an increase in lean body mass and free testosterone levels, and a decrease in SHBG levels compared to no-AI users. The mechanisms and implications of these changes need to be studied further.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-010-1223-2</identifier><identifier>PMID: 21046232</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Boston : Springer US</publisher><subject>Adipose Tissue - physiology ; Adjuvant treatment ; Analysis ; Aromatase inhibitors ; Aromatase Inhibitors - administration & dosage ; Aromatase Inhibitors - therapeutic use ; Biological and medical sciences ; body composition ; Body Composition - drug effects ; Body fat ; Body Mass Index ; Bone Density - drug effects ; Breast cancer ; breast neoplasms ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Breast Neoplasms - physiopathology ; Cancer ; Cancer research ; Cancer therapies ; Clinical Trial ; Clinical trials ; Double-Blind Method ; Estrogen ; Etidronic Acid - analogs & derivatives ; Etidronic Acid - therapeutic use ; Female ; Gonadal hormones ; Gonadal Hormones - blood ; Gynecology. Andrology. Obstetrics ; Hormones ; Humans ; Impact analysis ; Inhibitor drugs ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Menopause ; Middle Aged ; Oncology ; Physiological aspects ; Placebos ; Postmenopausal women ; Postmenopause ; Risedronate Sodium ; Sex Hormone-Binding Globulin - analysis ; Testosterone ; Tumors</subject><ispartof>Breast cancer research and treatment, 2011-01, Vol.125 (2), p.441-446</ispartof><rights>Springer Science+Business Media, LLC. 2010</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Springer</rights><rights>Springer Science+Business Media, LLC. 2011</rights><rights>Springer Science+Business Media, LLC. 2010 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c620t-8229411b0a6325e8039d0874e702f7ab58df2665af4382cb690ca6988566c2203</citedby><cites>FETCH-LOGICAL-c620t-8229411b0a6325e8039d0874e702f7ab58df2665af4382cb690ca6988566c2203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-010-1223-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-010-1223-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23747314$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21046232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Londen, G. J</creatorcontrib><creatorcontrib>Perera, S</creatorcontrib><creatorcontrib>Vujevich, K</creatorcontrib><creatorcontrib>Rastogi, P</creatorcontrib><creatorcontrib>Lembersky, B</creatorcontrib><creatorcontrib>Brufsky, A</creatorcontrib><creatorcontrib>Vogel, V</creatorcontrib><creatorcontrib>Greenspan, S. L</creatorcontrib><title>impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailable estrogens by inhibiting aromatase, which would be expected to induce alterations in body composition, more extensive than induced by menopause. The objectives are to examine the impact of AIs on (1) DXA-scan derived body composition and (2) gonadal hormone levels. This is a sub-analysis of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate (35 mg once weekly) versus placebo, and stratified for their usage of AI versus no AI. Outcomes included DXA-scan derived body composition and gonadal hormone levels. As a group, total body mass increased in women over 24 months. Women on AIs gained a significant amount of lean body mass compared to baseline as well as to no-AI users (P < 0.05). Women not on an AI gained total body fat compared to baseline and AI users (P < 0.05). Free testosterone significantly increased and sex hormone binding globulin (SHBG) significantly decreased in women on AIs compared to no AIs at 24 months (P < 0.01) while total estradiol and testosterone levels remained stable. Independent of AI usage, chemotherapy-induced postmenopausal breast cancer patients demonstrated an increase of total body mass. AI users demonstrated maintenance of total body fat, an increase in lean body mass and free testosterone levels, and a decrease in SHBG levels compared to no-AI users. The mechanisms and implications of these changes need to be studied further.</description><subject>Adipose Tissue - physiology</subject><subject>Adjuvant treatment</subject><subject>Analysis</subject><subject>Aromatase inhibitors</subject><subject>Aromatase Inhibitors - administration & dosage</subject><subject>Aromatase Inhibitors - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>body composition</subject><subject>Body Composition - drug effects</subject><subject>Body fat</subject><subject>Body Mass Index</subject><subject>Bone Density - drug effects</subject><subject>Breast cancer</subject><subject>breast neoplasms</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - physiopathology</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Clinical Trial</subject><subject>Clinical trials</subject><subject>Double-Blind Method</subject><subject>Estrogen</subject><subject>Etidronic Acid - analogs & derivatives</subject><subject>Etidronic Acid - therapeutic use</subject><subject>Female</subject><subject>Gonadal hormones</subject><subject>Gonadal Hormones - blood</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormones</subject><subject>Humans</subject><subject>Impact analysis</subject><subject>Inhibitor drugs</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Menopause</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Physiological aspects</subject><subject>Placebos</subject><subject>Postmenopausal women</subject><subject>Postmenopause</subject><subject>Risedronate Sodium</subject><subject>Sex Hormone-Binding Globulin - analysis</subject><subject>Testosterone</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kl9vFCEUxSdGY7fVD-CLEo2-Tb3ADDAvTZqm_kma-KB9JncYZoc6AyvM1vTby2bWtpsYQwIBfucAh1sUryicUgD5MVGoq6YECiVljJfsSbGiteSlZFQ-LVZAhSyFAnFUHKd0AwCNhOZ5ccQoVIJxtip-ummDZiahJ-gJxjDhjMkS5wfXujlEEjxpQ3dHTJg2IbnZ5QX0HVkHjx2OZAhxCt6S0d7aMWUh-R0mm3s3D6SNFtNMDHpj44viWY9jsi_340lx_enyx8WX8urb568X51elEQzmUjHWVJS2gIKz2irgTQdKVlYC6yW2tep6JkSNfcUVM61owKBolKqFMIwBPynOFt_Ntp1sZ6yfI456E92E8U4HdPpwx7tBr8Ot5hS4lCIbvN0bxPBra9Osb8I2-nxnrRjlIEDwDL1boDWOVjvfh-xlJpeMPue14HW-o8zU6T-o3Do7OZNz611ePxB8eCQYLI7zkMK43eWeDkG6gCaGlKLt7x9IQe_KQy_loWE3z-WhWda8fpzMveJvPWTg_R7AZHDsY_44lx44LivJaZU5tnApb_m1jQ8J_e_0N4uox6BxHbPx9XcGOVDaMKpqyv8AIjvZaA</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>van Londen, G. J</creator><creator>Perera, S</creator><creator>Vujevich, K</creator><creator>Rastogi, P</creator><creator>Lembersky, B</creator><creator>Brufsky, A</creator><creator>Vogel, V</creator><creator>Greenspan, S. L</creator><general>Boston : Springer US</general><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20110101</creationdate><title>impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer</title><author>van Londen, G. J ; Perera, S ; Vujevich, K ; Rastogi, P ; Lembersky, B ; Brufsky, A ; Vogel, V ; Greenspan, S. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c620t-8229411b0a6325e8039d0874e702f7ab58df2665af4382cb690ca6988566c2203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adipose Tissue - physiology</topic><topic>Adjuvant treatment</topic><topic>Analysis</topic><topic>Aromatase inhibitors</topic><topic>Aromatase Inhibitors - administration & dosage</topic><topic>Aromatase Inhibitors - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>body composition</topic><topic>Body Composition - drug effects</topic><topic>Body fat</topic><topic>Body Mass Index</topic><topic>Bone Density - drug effects</topic><topic>Breast cancer</topic><topic>breast neoplasms</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - physiopathology</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Clinical Trial</topic><topic>Clinical trials</topic><topic>Double-Blind Method</topic><topic>Estrogen</topic><topic>Etidronic Acid - analogs & derivatives</topic><topic>Etidronic Acid - therapeutic use</topic><topic>Female</topic><topic>Gonadal hormones</topic><topic>Gonadal Hormones - blood</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormones</topic><topic>Humans</topic><topic>Impact analysis</topic><topic>Inhibitor drugs</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Menopause</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Physiological aspects</topic><topic>Placebos</topic><topic>Postmenopausal women</topic><topic>Postmenopause</topic><topic>Risedronate Sodium</topic><topic>Sex Hormone-Binding Globulin - analysis</topic><topic>Testosterone</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Londen, G. J</creatorcontrib><creatorcontrib>Perera, S</creatorcontrib><creatorcontrib>Vujevich, K</creatorcontrib><creatorcontrib>Rastogi, P</creatorcontrib><creatorcontrib>Lembersky, B</creatorcontrib><creatorcontrib>Brufsky, A</creatorcontrib><creatorcontrib>Vogel, V</creatorcontrib><creatorcontrib>Greenspan, S. L</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Family Health</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Londen, G. J</au><au>Perera, S</au><au>Vujevich, K</au><au>Rastogi, P</au><au>Lembersky, B</au><au>Brufsky, A</au><au>Vogel, V</au><au>Greenspan, S. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>125</volume><issue>2</issue><spage>441</spage><epage>446</epage><pages>441-446</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailable estrogens by inhibiting aromatase, which would be expected to induce alterations in body composition, more extensive than induced by menopause. The objectives are to examine the impact of AIs on (1) DXA-scan derived body composition and (2) gonadal hormone levels. This is a sub-analysis of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate (35 mg once weekly) versus placebo, and stratified for their usage of AI versus no AI. Outcomes included DXA-scan derived body composition and gonadal hormone levels. As a group, total body mass increased in women over 24 months. Women on AIs gained a significant amount of lean body mass compared to baseline as well as to no-AI users (P < 0.05). Women not on an AI gained total body fat compared to baseline and AI users (P < 0.05). Free testosterone significantly increased and sex hormone binding globulin (SHBG) significantly decreased in women on AIs compared to no AIs at 24 months (P < 0.01) while total estradiol and testosterone levels remained stable. Independent of AI usage, chemotherapy-induced postmenopausal breast cancer patients demonstrated an increase of total body mass. AI users demonstrated maintenance of total body fat, an increase in lean body mass and free testosterone levels, and a decrease in SHBG levels compared to no-AI users. The mechanisms and implications of these changes need to be studied further.</abstract><cop>Boston</cop><pub>Boston : Springer US</pub><pmid>21046232</pmid><doi>10.1007/s10549-010-1223-2</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2011-01, Vol.125 (2), p.441-446 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3103776 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Adipose Tissue - physiology Adjuvant treatment Analysis Aromatase inhibitors Aromatase Inhibitors - administration & dosage Aromatase Inhibitors - therapeutic use Biological and medical sciences body composition Body Composition - drug effects Body fat Body Mass Index Bone Density - drug effects Breast cancer breast neoplasms Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - physiopathology Cancer Cancer research Cancer therapies Clinical Trial Clinical trials Double-Blind Method Estrogen Etidronic Acid - analogs & derivatives Etidronic Acid - therapeutic use Female Gonadal hormones Gonadal Hormones - blood Gynecology. Andrology. Obstetrics Hormones Humans Impact analysis Inhibitor drugs Mammary gland diseases Medical sciences Medicine Medicine & Public Health Menopause Middle Aged Oncology Physiological aspects Placebos Postmenopausal women Postmenopause Risedronate Sodium Sex Hormone-Binding Globulin - analysis Testosterone Tumors |
| title | impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T10%3A09%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=impact%20of%20an%20aromatase%20inhibitor%20on%20body%20composition%20and%20gonadal%20hormone%20levels%20in%20women%20with%20breast%20cancer&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=van%20Londen,%20G.%20J&rft.date=2011-01-01&rft.volume=125&rft.issue=2&rft.spage=441&rft.epage=446&rft.pages=441-446&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-010-1223-2&rft_dat=%3Cgale_pubme%3EA356352667%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=821306063&rft_id=info:pmid/21046232&rft_galeid=A356352667&rfr_iscdi=true |